Here, we report the draft genome sequence and characterization of the commercial strain Escherichia coli DSM 12242 (ϭATCC 13706/60 ϭNZRM 3262) derived from strain C (ATCC 13706), which is suitable for the isolation of coliphages from environmental and clinical samples.
Strain DSM 12242 has a draft genome of 4,542,748 bp and a GC content of 50.9%. The genome coverage was calculated as 82.2ϫ. Annotation with Prokka 1.13.3 (11) revealed the presence of 4,476 genes, 4,174 coding sequences, 11 rRNAs, 81 tRNAs, and 2 CRISPR repeats. Based on the in silico data, the multilocus sequence type (ST) and predicted serotype were ST 1721 (12, 13) and NT:H19 (14), respectively. ResFinder (15) identified the presence of mdfA (99.92% identity), a gene that encodes a multidrug resistance efflux pump. No plasmid sequences were detected using PlasmidFinder (16) . The PHASTER prophage finder (17) identified two incomplete prophage regions of 8.2 kb and 16.7 kb. OrthoANI (18) revealed that this bacterium shares an average nucleotide identity of 98.99% with E. coli C (GenBank accession no. CP029371) (19) and 99.97% with strain WG5 (GenBank accession no. CP024090) (20) . Nalidixic acid resistance is conferred to strain DSM 12242 by a single point mutation (Asp87¡Gly) in the gyrA gene, while in strain WG5, it is associated with two point mutations (Asp87¡Gly and Gln-106¡His) (15) .
Data availability. The genome sequence has been deposited in GenBank under the accession no. VNIO00000000, and the version described in this paper is the first version (VNIO01000000). The Illumina raw reads have been deposited in the SRA under the accession no. SRR9717097.
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